Biotechnology company Transgene (Euronext Paris: TNG) announced on Wednesday that it has started the Delivir trial, its Phase I clinical study evaluating TG6050, an oncolytic virus.

Transgene said TG6050 has been developed with the company's Invir.IO platform to deliver an interleukin-12 (IL-12) payload and an anti-CTLA4 antibody, potentially activating a powerful anti-tumour immune response.

The intravenous (IV) administration of TG6050 will be evaluated in up to 36 patients with recurrent metastatic non-small cell lung cancer (NSCLC). Intra-tumoural concentrations of IL-12 and anti-CTLA4 antibody and oncolysis can activate immune responses. Intravenous administration also allows for broader use in more tumour types. The Delivir trial is expected to be completed in H2 2024.

Preclinical and toxicology studies showed that the data demonstrated efficacy and safety.